# US 2020/0369772 A1 · Anti-human pd-l2 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369772 A1
- Document ID: US20200369772A1
- Status: Published application
- Kind: A1
- Application number: 16/969,873
- Filed: 2019-02-14
- Published: 2020-11-26
- Earliest claimed: 2018-02-14
- Assignees: Abba Therapeutics AG
- Applicants: Abba Therapeutics AG
- Inventors: Reto Simon KOHLER; Gongda XUE; Lena CRON
- Web page: https://patentgrep.com/patent/US20200369772A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to anti-human PD-L2 antibodies, or the antigen binding parts thereof, which specifically bind human PD-L2 such that PD-L2 binding to PD-1 is blocked, wherein preferably said antibodies or antigen binding parts do not bind to mouse PD-L2 and human PD-L1 but bind to cyno PD-L2, preferably as determined by FACS analysis. The present invention also relates to nucleotide sequences encoding the anti-human PD-L2 antibodies, vectors and cells containing the nucleotide sequences. The antibodies and/or compositions of the invention are useful in human therapy, e.g., cancer therapy, and/or in cell-line based bioassays for determining T cell signalling.

## Claims

### Claim 1

An anti-human PD-L2 antibody or the antigen binding part thereof, which specifically binds human PD-L2 such that PD-L2 binding to PD-1 is blocked,
wherein the antibody, or antigen binding part thereof, comprises six CDR sequences comprised in the heavy chain variable regions and light chain variable regions, respectively, as defined in any of the below items a) to q), or
wherein the antibody, or antigen binding part thereof, comprises six CDR sequences comprised in the heavy chain variable regions and light chain variable regions, respectively, as defined in any of the below items a) to q), wherein up to 1,2,3 amino acid residues in the CDR sequences are substituted:
a) a heavy chain variable region which has the sequence of SEQ ID NO: 2 and a light chain variable region which has the sequence of SEQ ID NO: 10;
b) a heavy chain variable region which has the sequence of SEQ ID NO: 18 and a light chain variable region which has the sequence of SEQ ID NO: 26;
c) a heavy chain variable region which has the sequence of SEQ ID NO: 34 and a light chain variable region which has the sequence of SEQ ID NO: 42;
d) a heavy chain variable region which has the sequence of SEQ ID NO: 50 and a light chain variable region which has the sequence of SEQ ID NO: 58;
e) a heavy chain variable region which has the sequence of SEQ ID NO: 50 and a light chain variable region which has the sequence of SEQ ID NO: 66;
f) a heavy chain variable region which has the sequence of SEQ ID NO: 96 and a light chain variable region which has the sequence of SEQ ID NO: 104;
g) a heavy chain variable region which has the sequence of SEQ ID NO: 112 and a light chain variable region which has the sequence of SEQ ID NO: 120;
h) a heavy chain variable region which has the sequence of SEQ ID NO: 128 and a light chain variable region which has the sequence of SEQ ID NO: 132;
i) a heavy chain variable region which has the sequence of SEQ ID NO: 140 and a light chain variable region which has the sequence of SEQ ID NO: 146;
j) a heavy chain variable region which has the sequence of SEQ ID NO: 152 and a light chain variable region which has the sequence of SEQ ID NO: 160;
k) a heavy chain variable region which has the sequence of SEQ ID NO: 166 and a light chain variable region which has the sequence of SEQ ID NO: 174;
l) a heavy chain variable region which has the sequence of SEQ ID NO: 96 and a light chain variable region which has the sequence of SEQ ID NO: 212;
m) a heavy chain variable region which has the sequence of SEQ ID NO: 140 and a light chain variable region which has the sequence of SEQ ID NO: 218;
n) a heavy chain variable region which has the sequence of SEQ ID NO: 220 and a light chain variable region which has the sequence of SEQ ID NO: 160;
o) a heavy chain variable region which has the sequence of SEQ ID NO: 220 and a light chain variable region which has the sequence of SEQ ID NO: 26;
p) a heavy chain variable region which has the sequence of SEQ ID NO: 220 and a light chain variable region which has the sequence of SEQ ID NO: 226; or
q) a heavy chain variable region which has the sequence of SEQ ID NO: 220 and a light chain variable region which has the sequence of SEQ ID NO: 230.

### Claim 2 (depends on 1)

The antibody or antigen binding part according to claim 1, which comprises three heavy chain CDRs and three light chain CDRs comprising
a) CDR-H1 of SEQ ID NO: 4, CDR-H2 of SEQ ID NO: 6, CDR-H3 of SEQ ID NO: 8 and CDR-L1 of SEQ ID NO: 12, CDR-L2 of SEQ ID NO: 14, CDR-L3 of SEQ ID NO: 16; or
b) CDR-H1 of SEQ ID NO: 20, CDR-H2 of SEQ ID NO: 22, CDR-H3 of SEQ ID NO: 24 and CDR-L1 of SEQ ID NO: 28, CDR-L2 of SEQ ID NO: 30, CDR-L3 of SEQ ID NO: 32; or
c) CDR-H1 of SEQ ID NO: 36, CDR-H2 of SEQ ID NO: 38, CDR-H3 of SEQ ID NO: 40 and CDR-L1 of SEQ ID NO: 44, CDR-L2 of SEQ ID NO: 46, CDR-L3 of SEQ ID NO: 48; or
d) CDR-H1 of SEQ ID NO: 52, CDR-H2 of SEQ ID NO: 54, CDR-H3 of SEQ ID NO: 56 and CDR-L1 of SEQ ID NO: 60, CDR-L2 of SEQ ID NO: 62, CDR-L3 of SEQ ID NO: 64; or
e) CDR-H1 of SEQ ID NO: 52, CDR-H2 of SEQ ID NO: 54, CDR-H3 of SEQ ID NO: 56 and CDR-L1 of SEQ ID NO: 60, CDR-L2 of SEQ ID NO: 62, CDR-L3 of SEQ ID NO: 68; or
f) CDR-H1 of SEQ ID NO: 98, CDR-H2 of SEQ ID NO: 100, CDR-H3 of SEQ ID NO: 102 and CDR-L1 of SEQ ID NO: 106, CDR-L2 of SEQ ID NO: 108, CDR-L3 of SEQ ID NO: 110; or
g) CDR-H1 of SEQ ID NO: 114, CDR-H2 of SEQ ID NO: 116, CDR-H3 of SEQ ID NO: 118 and CDR-L1 of SEQ ID NO: 122, CDR-L2 of SEQ ID NO: 124, CDR-L3 of SEQ ID NO: 126; or
h) CDR-H1 of SEQ ID NO: 114, CDR-H2 of SEQ ID NO: 130, CDR-H3 of SEQ ID NO: 118 and CDR-L1 of SEQ ID NO: 134, CDR-L2 of SEQ ID NO: 136, CDR-L3 of SEQ ID NO: 138; or
i) CDR-H1 of SEQ ID NO: 98, CDR-H2 of SEQ ID NO: 142, CDR-H3 of SEQ ID NO: 144 and CDR-L1 of SEQ ID NO: 106, CDR-L2 of SEQ ID NO: 148, CDR-L3 of SEQ ID NO: 150; or
j) CDR-H1 of SEQ ID NO: 154, CDR-H2 of SEQ ID NO: 156, CDR-H3 of SEQ ID NO: 158 and CDR-L1 of SEQ ID NO: 162, CDR-L2 of SEQ ID NO: 30, CDR-L3 of SEQ ID NO: 164; or
k) CDR-H1 of SEQ ID NO: 168, CDR-H2 of SEQ ID NO: 170, CDR-H3 of SEQ ID NO: 172 and CDR-L1 of SEQ ID NO: 176, CDR-L2 of SEQ ID NO: 178, CDR-L3 of SEQ ID NO: 180; or
l) CDR-H1 of SEQ ID NO: 98, CDR-H2 of SEQ ID NO: 100, CDR-H3 of SEQ ID NO: 102 and CDR-L1 of SEQ ID NO: 214, CDR-L2 of SEQ ID NO: 108, CDR-L3 of SEQ ID NO: 216; or
m) CDR-H1 of SEQ ID NO: 98, CDR-H2 of SEQ ID NO: 142, CDR-H3 of SEQ ID NO: 144 and CDR-L1 of SEQ ID NO: 214, CDR-L2 of SEQ ID NO: 148, CDR-L3 of SEQ ID NO: 150; or
n) CDR-H1 of SEQ ID NO: 154, CDR-H2 of SEQ ID NO: 222, CDR-H3 of SEQ ID NO: 158 and CDR-L1 of SEQ ID NO: 162, CDR-L2 of SEQ ID NO: 30, CDR-L3 of SEQ ID NO: 164; or
o) CDR-H1 of SEQ ID NO: 154, CDR-H2 of SEQ ID NO: 222, CDR-H3 of SEQ ID NO: 158 and CDR-L1 of SEQ ID NO: 28, CDR-L2 of SEQ ID NO: 30, CDR-L3 of SEQ ID NO: 32; or
o) CDR-H1 of SEQ ID NO: 154, CDR-H2 of SEQ ID NO: 222, CDR-H3 of SEQ ID NO: 158 and CDR-L1 of SEQ ID NO: 28, CDR-L2 of SEQ ID NO: 30, CDR-L3 of SEQ ID NO: 228; or
p) CDR-H1 of SEQ ID NO: 154, CDR-H2 of SEQ ID NO: 222, CDR-H3 of SEQ ID NO: 158 and CDR-L1 of SEQ ID NO: 162, CDR-L2 of SEQ ID NO: 30, CDR-L3 of SEQ ID NO: 32; or
r) a variant of the CDR-H1 and the CDR-H2 and the CDR-H3 and the CDR-L1 and the CDR-L2 and the CDR-L3 as shown in a) to
q), wherein up to 1,2,3 amino acid residues in the CDR sequences are substituted.

### Claim 3 (depends on 1, 2)

The antibody or antigen binding part according to claim 1 or 2, which comprises a heavy chain variable region and a light chain variable region, wherein the
a) heavy chain variable region has the sequence of SEQ ID NO: 2 and the light chain variable region has the sequence of SEQ ID NO: 10;
b) heavy chain variable region has the sequence of SEQ ID NO: 18 and the light chain variable region has the sequence of SEQ ID NO: 26;
c) heavy chain variable region has the sequence of SEQ ID NO: 34 and the light chain variable region has the sequence of SEQ ID NO: 42;
d) heavy chain variable region has the sequence of SEQ ID NO: 50 and the light chain variable region has the sequence of SEQ ID NO: 58;
e) heavy chain variable region has the sequence of SEQ ID NO: 50 and the light chain variable region has the sequence of SEQ ID NO: 66;
f) heavy chain variable region has the sequence of SEQ ID NO: 96 and the light chain variable region has the sequence of SEQ ID NO: 104;
g) heavy chain variable region has the sequence of SEQ ID NO: 112 and the light chain variable region has the sequence of SEQ ID NO: 120;
h) heavy chain variable region has the sequence of SEQ ID NO: 128 and the light chain variable region has the sequence of SEQ ID NO: 132;
i) heavy chain variable region has the sequence of SEQ ID NO: 140 and the light chain variable region has the sequence of SEQ ID NO: 146;
j) heavy chain variable region has the sequence of SEQ ID NO: 152 and the light chain variable region has the sequence of SEQ ID NO: 160;
k) heavy chain variable region has the sequence of SEQ ID NO: 166 and the light chain variable region has the sequence of SEQ ID NO: 174;
l) heavy chain variable region has the sequence of SEQ ID NO: 96 and the light chain variable region has the sequence of SEQ ID NO: 212;
m) heavy chain variable region has the sequence of SEQ ID NO: 140 and the light chain variable region has the sequence of SEQ ID NO: 218;
n) heavy chain variable region has the sequence of SEQ ID NO: 220 and the light chain variable region has the sequence of SEQ ID NO: 160;
o) heavy chain variable region has the sequence of SEQ ID NO: 220 and the light chain variable region has the sequence of SEQ ID NO: 26;
p) heavy chain variable region has the sequence of SEQ ID NO: 220 and the light chain variable region has the sequence of SEQ ID NO: 226;
q) heavy chain variable region has the sequence of SEQ ID NO: 220 and the light chain variable region has the sequence of SEQ ID NO: 230; or
r) a variant of the heavy chain variable region and/or the light chain variable region as shown in a) to q), wherein the variant sequence has an overall homology of 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%%, with the proviso that up to 1,2,3 amino acid residues in the CDR sequences are substituted.

### Claim 4

The antibody or antigen binding part thereof, according to any one of the preceding claims, which antibody or antigen binding part fulfils at least one, preferably 2, 3 or 4 of the functional features listed in a) to d)
a) higher binding affinity to PD-L2 compared to the reference antibodies MIH18 and 24F.10C12;
b) more efficient blocking of PD-L2 binding to PD-1 compared to the reference antibodies MIH18 and 24F.10C12;
c) more efficient activation of TCR-mediated IL-2 expression compared to the reference antibodies MIH18 and 24F.10C12; and
d) induction of higher IL-2 levels upon TCR-mediated IL-2 expression compared to the reference antibodies MIH18 and 24F.10C12.

### Claim 5

The antibody or antigen binding part thereof, according to any one of the preceding claims, which is a humanized or a fully human antibody.

### Claim 6

The antibody or antigen binding part according to any one of the preceding claims, which is of the IgG1, IgG2, IgG3 or IgG4 isotype.

### Claim 7

The antibody or antigen binding part according to any one of the preceding claims, which is of the IgG1 isotype.

### Claim 8

The antibody or antigen binding part according to any one of the preceding claims, wherein the antibody or antigen binding part is a monospecific, bispecific, trispecific or multispecific antibody or antigen binding part thereof.

### Claim 9

The antibody or antigen binding part according to any one of the preceding claims, wherein the antibody or antigen binding part thereof blocks the binding to PD-L2 to another receptor than PD-1.

### Claim 10

An antibody or antigen binding part thereof, which binds to the same epitope and/or competes for the same epitope with any of the antibodies or antigen binding parts of any of the preceding claims.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A nucleic acid molecule comprising a nucleotide sequence encoding the antibody or antigen binding fragment thereof according to any one of claims 1 to 10.

### Claim 12 (depends on 11)

The nucleic acid molecule of claim 11 which comprises a nucleotide sequence encoding three heavy chain CDRs and three light chain CDRs comprising
a) CDR-H1 of SEQ ID NO: 3, CDR-H2 of SEQ ID NO: 5, CDR-H3 of SEQ ID NO: 7 and CDR-L1 of SEQ ID NO: 11, CDR-L2 of SEQ ID NO: 13, CDR-L3 of SEQ ID NO: 15; or
b) CDR-H1 of SEQ ID NO: 19, CDR-H2 of SEQ ID NO: 21, CDR-H3 of SEQ ID NO: 23 and CDR-L1 of SEQ ID NO: 27, CDR-L2 of SEQ ID NO: 29, CDR-L3 of SEQ ID NO: 31; or
c) CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 37, CDR-H3 of SEQ ID NO: 39 and CDR-L1 of SEQ ID NO: 43, CDR-L2 of SEQ ID NO: 45, CDR-L3 of SEQ ID NO: 47; or
d) CDR-H1 of SEQ ID NO: 51, CDR-H2 of SEQ ID NO: 53, CDR-H3 of SEQ ID NO: 55 and CDR-L1 of SEQ ID NO: 59, CDR-L2 of SEQ ID NO: 61, CDR-L3 of SEQ ID NO: 63; or
e) CDR-H1 of SEQ ID NO: 51, CDR-H2 of SEQ ID NO: 53, CDR-H3 of SEQ ID NO: 55 and CDR-L1 of SEQ ID NO: 59, CDR-L2 of SEQ ID NO: 61, CDR-L3 of SEQ ID NO: 67; or
f) CDR-H1 of SEQ ID NO: 97, CDR-H2 of SEQ ID NO: 99, CDR-H3 of SEQ ID NO: 101 and CDR-L1 of SEQ ID NO: 105, CDR-L2 of SEQ ID NO: 107, CDR-L3 of SEQ ID NO: 109; or
g) CDR-H1 of SEQ ID NO: 113, CDR-H2 of SEQ ID NO: 115, CDR-H3 of SEQ ID NO: 117 and CDR-L1 of SEQ ID NO: 121, CDR-L2 of SEQ ID NO: 123, CDR-L3 of SEQ ID NO: 125; or
h) CDR-H1 of SEQ ID NO: 113, CDR-H2 of SEQ ID NO: 129, CDR-H3 of SEQ ID NO: 117 and CDR-L1 of SEQ ID NO: 133, CDR-L2 of SEQ ID NO: 135, CDR-L3 of SEQ ID NO: 137; or
i) CDR-H1 of SEQ ID NO: 97, CDR-H2 of SEQ ID NO: 141, CDR-H3 of SEQ ID NO: 143 and CDR-L1 of SEQ ID NO: 105, CDR-L2 of SEQ ID NO: 147, CDR-L3 of SEQ ID NO: 149; or
j) CDR-H1 of SEQ ID NO: 153, CDR-H2 of SEQ ID NO: 155, CDR-H3 of SEQ ID NO: 157 and CDR-L1 of SEQ ID NO: 161, CDR-L2 of SEQ ID NO: 29, CDR-L3 of SEQ ID NO: 163; or
k) CDR-H1 of SEQ ID NO: 167, CDR-H2 of SEQ ID NO: 169, CDR-H3 of SEQ ID NO: 171 and CDR-L1 of SEQ ID NO: 175, CDR-L2 of SEQ ID NO: 177, CDR-L3 of SEQ ID NO: 179; or
l) CDR-H1 of SEQ ID NO: 97, CDR-H2 of SEQ ID NO: 99, CDR-H3 of SEQ ID NO: 101 and CDR-L1 of SEQ ID NO: 213, CDR-L2 of SEQ ID NO: 107, CDR-L3 of SEQ ID NO: 215; or
m) CDR-H1 of SEQ ID NO: 97, CDR-H2 of SEQ ID NO: 141, CDR-H3 of SEQ ID NO: 143 and CDR-L1 of SEQ ID NO: 213, CDR-L2 of SEQ ID NO: 147, CDR-L3 of SEQ ID NO: 149; or
n) CDR-H1 of SEQ ID NO: 153, CDR-H2 of SEQ ID NO: 221, CDR-H3 of SEQ ID NO: 157 and CDR-L1 of SEQ ID NO: 161, CDR-L2 of SEQ ID NO: 29, CDR-L3 of SEQ ID NO: 163; or
o) CDR-H1 of SEQ ID NO: 153, CDR-H2 of SEQ ID NO: 221, CDR-H3 of SEQ ID NO: 157 and CDR-L1 of SEQ ID NO: 27, CDR-L2 of SEQ ID NO: 29, CDR-L3 of SEQ ID NO: 31; or
p) CDR-H1 of SEQ ID NO: 153, CDR-H2 of SEQ ID NO: 221, CDR-H3 of SEQ ID NO: 157 and CDR-L1 of SEQ ID NO: 161, CDR-L2 of SEQ ID NO: 29, CDR-L3 of SEQ ID NO: 227; or
q) CDR-H1 of SEQ ID NO: 153, CDR-H2 of SEQ ID NO: 221, CDR-H3 of SEQ ID NO: 157 and CDR-L1 of SEQ ID NO: 161, CDR-L2 of SEQ ID NO: 29, CDR-L3 of SEQ ID NO: 31.

### Claim 13 (depends on 11)

The nucleic acid molecule of claim 11 which comprises a nucleotide sequence encoding a heavy chain variable region and a light chain variable region, wherein the
a) heavy chain variable region has the sequence of SEQ ID NO: 1 and the light chain variable region has the sequence of SEQ ID NO: 9;
b) heavy chain variable region has the sequence of SEQ ID NO: 17 and the light chain variable region has the sequence of SEQ ID NO: 25;
c) heavy chain variable region has the sequence of SEQ ID NO: 33 and the light chain variable region has the sequence of SEQ ID NO: 41;
d) heavy chain variable region has the sequence of SEQ ID NO: 49 and the light chain variable region has the sequence of SEQ ID NO: 57;
e) heavy chain variable region has the sequence of SEQ ID NO: 49 and the light chain variable region has the sequence of SEQ ID NO: 65;
f) heavy chain variable region has the sequence of SEQ ID NO: 95 and the light chain variable region has the sequence of SEQ ID NO: 103;
g) heavy chain variable region has the sequence of SEQ ID NO: 111 and the light chain variable region has the sequence of SEQ ID NO: 119;
h) heavy chain variable region has the sequence of SEQ ID NO: 127 and the light chain variable region has the sequence of SEQ ID NO: 131;
i) heavy chain variable region has the sequence of SEQ ID NO: 139 and the light chain variable region has the sequence of SEQ ID NO: 145;
j) heavy chain variable region has the sequence of SEQ ID NO: 151 and the light chain variable region has the sequence of SEQ ID NO: 159;
k) heavy chain variable region has the sequence of SEQ ID NO: 165 and the light chain variable region has the sequence of SEQ ID NO: 173;
l) heavy chain variable region has the sequence of SEQ ID NO: 95 and the light chain variable region has the sequence of SEQ ID NO: 211;
m) heavy chain variable region has the sequence of SEQ ID NO: 139 and the light chain variable region has the sequence of SEQ ID NO: 217;
n) heavy chain variable region has the sequence of SEQ ID NO: 219 and the light chain variable region has the sequence of SEQ ID NO: 159;
o) heavy chain variable region has the sequence of SEQ ID NO: 219 and the light chain variable region has the sequence of SEQ ID NO: 25;
p) heavy chain variable region has the sequence of SEQ ID NO: 219 and the light chain variable region has the sequence of SEQ ID NO: 225; or
q) heavy chain variable region has the sequence of SEQ ID NO: 219 and the light chain variable region has the sequence of SEQ ID NO: 229.

### Claim 14 (depends on 11, 12, 13)

An expression vector comprising the nucleotide sequence of any one of claims 11 to 13.

### Claim 15 (depends on 14)

A cell comprising the expression vector of claim 14.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition comprising the antibody or antigen binding fragment thereof according to any one of claims 1 to 10.

### Claim 17 (depends on 11, 12, 13, 14)

A pharmaceutical composition comprising the nucleic acid molecule of any one of claims 11 to 13 or the expression vector of claim 14.

### Claim 18 (depends on 16, 17)

The pharmaceutical composition of claim 16 or claim 17 further comprising a pharmaceutically acceptable carrier and/or excipient.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18)

The antibody or antigen binding part according to any one of claims 1 to 10, the nucleic acid molecule of any one of claims 11 to 13, the expression vector of claim 14, or the pharmaceutical composition of any one of claims 16 to 18 for use in human therapy.

### Claim 20 (depends on 19)

The antibody or antigen binding part, the nucleic acid molecule, the expression vector, or the pharmaceutical composition for use according to claim 19, wherein the human therapy is cancer therapy.

### Claim 21 (depends on 19, 20)

The antibody or antigen binding part, the nucleic acid molecule, the expression vector, or the pharmaceutical composition for use according to claim 19 or claim 20, wherein the therapeutic effect is based on the blockage of the PD-1-PD-L2 interaction.

### Claim 22 (depends on 19, 20, 21)

The antibody or antigen binding part, the nucleic acid molecule, the expression vector, or the pharmaceutical composition for use according to claims 19 to 21, wherein the therapeutic effect further comprises antibody-dependent cellular cytotoxicity (ADCC).

### Claim 23 (depends on 19, 20, 21, 22)

The antibody or antigen binding part, the nucleic acid molecule, the expression vector, or the pharmaceutical composition for use according to any one of claims 19 to 22, in combination with other therapies, preferably such as chemotherapy, antibody therapy and/or radiation therapy.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A cell-line-based bioassay for determining T cell signalling in a system mimicking the interaction between APC (antigen presenting cells) and T cells using serial dilutions of an anti-human PD-L2 antibody of any one of claims 1 to 10.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24)

A kit comprising an anti-human PD-L2 antibody of any one of claim 1 to 10 for use in the assay of claim 24.
